{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=27",
    "query": {
      "intervention": "Control Vaccine 2",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 680,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T17:41:31.479Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05506969",
      "title": "Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plague, Pneumonic",
        "Plague",
        "Vaccine-Preventable Diseases"
      ],
      "interventions": [
        {
          "name": "rF1V-1018",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rF1V vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 200,
      "start_date": "2022-08-09",
      "completion_date": "2024-04-26",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 6,
      "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05506969"
    },
    {
      "nct_id": "NCT04498247",
      "title": "A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Disease (COVID-19)"
      ],
      "interventions": [
        {
          "name": "V591",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 263,
      "start_date": "2020-08-27",
      "completion_date": "2021-03-05",
      "has_results": true,
      "last_update_posted_date": "2021-12-23",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 4,
      "location_summary": "Hollywood, Florida • Wichita, Kansas • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04498247"
    },
    {
      "nct_id": "NCT05181709",
      "title": "A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Sodium Chloride",
          "type": "DRUG"
        },
        {
          "name": "NDV-HXP-S IN low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NDV-HXP-S IM low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NDV-HXP-S IN high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NDV-HXP-S IM high dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sean Liu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 35,
      "start_date": "2022-02-09",
      "completion_date": "2024-04-19",
      "has_results": false,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05181709"
    },
    {
      "nct_id": "NCT05683834",
      "title": "Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus Infection",
        "Infectious Mononucleosis",
        "Herpesvirus"
      ],
      "interventions": [
        {
          "name": "Matrix-M1 Adjuvant",
          "type": "DRUG"
        },
        {
          "name": "EBV gp350-Ferritin Vaccine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "18 Years to 25 Years"
      },
      "enrollment_count": 25,
      "start_date": "2023-09-22",
      "completion_date": "2026-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05683834"
    },
    {
      "nct_id": "NCT03854734",
      "title": "Healthy, Immunized Communities Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaccine Hesitancy",
        "Communicable Diseases in Children"
      ],
      "interventions": [
        {
          "name": "Community Event",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Educational Material",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2019-02-14",
      "completion_date": "2023-02-09",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03854734"
    },
    {
      "nct_id": "NCT01482052",
      "title": "Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Meningococcal Meningitis",
        "Meningococcal Infections"
      ],
      "interventions": [
        {
          "name": "meningococcal meningitis conjugate vaccine, quadrivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "JN-International Medical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-11",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-01-14",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 1,
      "location_summary": "Hanford, California",
      "locations": [
        {
          "city": "Hanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482052"
    },
    {
      "nct_id": "NCT01571960",
      "title": "Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GEO-D03 DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA/HIV62B (MVA62B) vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for GEO-D03 DNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for MVA62B:",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-04",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01571960"
    },
    {
      "nct_id": "NCT01857869",
      "title": "Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "GSK257049 Dosage 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK257049 Dosage 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sporozoite-infected mosquitoes challenge",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-05-20",
      "completion_date": "2014-12-16",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01857869"
    },
    {
      "nct_id": "NCT01245673",
      "title": "Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Prevnar- Pneumococcal Conjugate Vaccine (PCV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Activated/costimulated autologous T-cell",
          "type": "OTHER"
        },
        {
          "name": "Revlamid® (Lenalidomide)",
          "type": "DRUG"
        },
        {
          "name": "MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-05-10",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2020-04-06",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01245673"
    },
    {
      "nct_id": "NCT07464314",
      "title": "A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza, Human+COVID-19"
      ],
      "interventions": [
        {
          "name": "Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed Seasonal Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 225,
      "start_date": "2026-03-09",
      "completion_date": "2027-06-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-19T17:41:31.479Z",
      "location_count": 12,
      "location_summary": "Anniston, Alabama • Little Rock, Arkansas • Fair Oaks, California + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07464314"
    }
  ]
}